ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0107

Short-, Intermediate- and Long-Term Renal Outcomes in Hispanics from Puerto Rico with Lupus Nephritis: Induction Therapy with Cyclophosphamide vs. Mycophenolate Mofetil

Suheiry Márquez, Dahima Cintrón and Luis Vilá, University of Puerto Rico Medical Sciences Campus, San Juan, PR

Meeting: ACR Convergence 2022

Keywords: Disparities, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Healthcare Disparities in Rheumatology Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: The American College of Rheumatology (ACR) guidelines for the treatment of class III and class IV lupus nephritis (LN) recommend induction therapy with mycophenolate mofetil (MMF) over cyclophosphamide (CYC) for Hispanics. These guidelines were derived from studies that mainly included Hispanics from Mexican ancestry. However, it is uncertain if these recommendations can be generalized to all Hispanic populations as there are considerable genetic, sociodemographic, and clinical disparities among Hispanics with lupus. Thus, we sought to determine the short-, intermediate- and long-term renal outcomes among Hispanics from Puerto Rico with LN receiving these treatment modalities.

Methods: A cohort of adult Puerto Ricans with LN was studied. LN was defined as the presence of proteinuria >0.5 g per day, urinary cellular casts, and/or a renal biopsy consistent with LN. Demographic features, clinical manifestations, comorbidities, disease activity (per Systemic Lupus Erythematosus Disease Activity Index ([SLEDAI]), disease damage (per Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]), and pharmacologic treatment were gathered at LN onset (baseline). Renal response, chronic kidney disease staging (per National Kidney Foundation), progression to end-stage renal disease (ESRD), and mortality were ascertained at 6 monts,12 months and last study visit. Renal outcomes between patients treated with CYC and MMF were compared using Chi-square test, Fisher’s exact test, or Mann-Whitney test, as appropriate.

Results: The total LN cohort consisted of 154 patients of which 97 received induction therapy with CYC (n=49) or MMF (n=48). Table 1 shows the baseline features of both treatment groups. Patients treated with CYC had statistically significant higher disease activity, lower albumin levels, and more pyuria and proteinuria than those treated with MMF. Table 2 depicts the renal outcomes at 6 months, 12 months, and last visit. Six-months after induction therapy the overall renal response (complete or partial) was higher in patients treated with MMF compared to CYC. At 12-months and at last visit, no differences were found for all outcome measures. Among patients treated with CYC, 51% of patients were started on MMF after the induction phase. Conversely, in those initially treated with MMF 92% remained on MMF. A sub-analysis in patients with class III and class IV LN showed similar results.

Conclusion: In this group of Puerto Ricans with LN, MMF induction therapy was superior to CYC at 6 months. However, at 12 months and at last study visit, renal outcomes were similar between these treatment groups. Half of patients in the CYC group were started on MMF after CYC therapy. Thus, the intermediate- and long-term efficacy observed for the CYC group could be in part attributed to MMF therapy. Our results are consistent with ACR recommendations favoring MMF over CYC for the induction therapy of LN in Hispanics.

Supporting image 1

Supporting image 2


Disclosures: S. Márquez, None; D. Cintrón, None; L. Vilá, None.

To cite this abstract in AMA style:

Márquez S, Cintrón D, Vilá L. Short-, Intermediate- and Long-Term Renal Outcomes in Hispanics from Puerto Rico with Lupus Nephritis: Induction Therapy with Cyclophosphamide vs. Mycophenolate Mofetil [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/short-intermediate-and-long-term-renal-outcomes-in-hispanics-from-puerto-rico-with-lupus-nephritis-induction-therapy-with-cyclophosphamide-vs-mycophenolate-mofetil/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/short-intermediate-and-long-term-renal-outcomes-in-hispanics-from-puerto-rico-with-lupus-nephritis-induction-therapy-with-cyclophosphamide-vs-mycophenolate-mofetil/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology